東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Economic evaluation of cancer drugs ...

Khan, Iftekhar.

FindBook

Google Book

Amazon

博客來

Economic evaluation of cancer drugs = using clinical trial and real-world data /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Economic evaluation of cancer drugs/ Iftekhar Khan, Ralph Crott, and Zahid Bashir.
其他題名:	using clinical trial and real-world data /
作者:	Khan, Iftekhar.
其他作者:	Crott, Ralph.
出版者:	Boca Raton :CRC Press, : c2020.,
面頁冊數:	1 online resource.
標題:	Pharmaceutical industry. -
電子資源:	https://www.taylorfrancis.com/books/9780429155826
ISBN:	9780429155826

Economic evaluation of cancer drugs = using clinical trial and real-world data /
Khan, Iftekhar.

Economic evaluation of cancer drugsusing clinical trial and real-world data /[electronic resource] :Iftekhar Khan, Ralph Crott, and Zahid Bashir. - 1st ed. - Boca Raton :CRC Press,c2020. - 1 online resource. - Chapman & Hall/CRC biostatistics series. - Chapman & Hall/CRC biostatistics series..

Includes bibliographical references and index.

Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.

ISBN: 9780429155826Subjects--Topical Terms:

630829
Pharmaceutical industry.

LC Class. No.: RC270.8

Dewey Class. No.: 616.99406

Economic evaluation of cancer drugs = using clinical trial and real-world data /
LDR:03771cmm a2200349 a 4500 001 2247934
003 FlBoTFG
005 20190710081011.0
006 m o d
007 cr cnu---unuuu
008 211227s2020 flu ob 001 0 eng d
020 $a 9780429155826 $q (electronic bk.)
020 $a 0429155824 $q (electronic bk.)
020 $a 9780429546549 $q (electronic bk. ; $q Mobipocket)
020 $a 0429546548 $q (electronic bk. ; $q Mobipocket)
020 $a 9781498761314 $q (electronic bk. ; $q PDF)
020 $a 1498761313 $q (electronic bk. ; $q PDF)
020 $a 9780429531842 $q (electronic bk. ; $q EPUB)
020 $a 0429531842 $q (electronic bk. ; $q EPUB)
020 $z 9781498761307
035 $a 9780429155826
040 $a OCoLC-P $b eng $c OCoLC-P
050 4 $a RC270.8
082 0 4 $a 616.99406 $2 23
100 1 $a Khan, Iftekhar. $3 2184846
245 1 0 $a Economic evaluation of cancer drugs $h [electronic resource] : $b using clinical trial and real-world data / $c Iftekhar Khan, Ralph Crott, and Zahid Bashir.
250 $a 1st ed.
260 $a Boca Raton : $b CRC Press, $c c2020.
300 $a 1 online resource.
490 1 $a Chapman & Hall/CRC biostatistics series
504 $a Includes bibliographical references and index.
520 $a Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
588 $a Description based on print version record.
650 0 $a Pharmaceutical industry. $3 630829
650 0 $a Cancer $x Treatment $x Economic aspects. $3 3512544
700 1 $a Crott, Ralph. $3 3512542
700 1 $a Bashir, Zahid. $3 3512543
830 0 $a Chapman & Hall/CRC biostatistics series. $3 2018655
856 4 0 $u https://www.taylorfrancis.com/books/9780429155826